General Information of DTT (ID: TT8D13I)

DTT Name Complement factor D (CFD) DTT Info
Gene Name CFD

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
7 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALXN2040 DMLJ18Y Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [1]
Lampalizumab DMA2NYS Geographic retinal atrophy 9B78.9 Phase 3 [2]
ACH-4471 DMLVCZR Anaemia 3A90 Phase 2 [3]
BCX-9930 DMBNC1I Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [4]
Vemircopan DM3RZ9H Generalized myasthenia gravis 8C60 Phase 2 [5]
Anti-Factor D DM8ENKS Age-related macular degeneration 9B75.0 Phase 1/2 [6]
ALXN2080 DMQPZQB Discovery agent N.A. Phase 1 [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Clinical Trial Drug(s)
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
example 373 [WO2012093101] DMP8A5R Discovery agent N.A. Investigative [8]
HC3-1496 DM1BLCX Autoimmune diabetes 5A10 Investigative [9]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Dec 1;106(12):3188-3197.
2 In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT05116774) A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy. U.S.National Institutes of Health.
5 Clinical pipeline report, company report or official report of AstraZeneca
6 Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1. IDrugs. 2010 Jul;13(7):427-9.
7 Clinical pipeline report, company report or official report of Alexion
8 Factor D Inhibitors for the Treatment of AMD: Patent Highlight. ACS Med Chem Lett. 2012 Aug 27;3(10):781-2.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2842).